Sarepta reports Q1 adjusted EPS ($3.42) vs 72c last year

Reports Q1 revenue $744.9M, consensus $684.12M. “In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375.0 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,” said Doug Ingram, president and chief executive officer, Sarepta (SRPT) Therapeutics. “The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times. To that end, in addition to driving the launch of ELEVIDYS and the continued performance of our three approved PMO therapies, we continue to invest in our pipeline and look forward to a significant number of LGMD gene therapy approvals in the coming few years. We are also advancing our siRNA platform and look forward to proof of concept and proof of biology readouts later this year in both our DM1 and FSHD1 programs.”